Snapshot
Halozyme Therapeutics, Inc. reported $377M of revenue in Q1 2026, up 42.2% year over year, with diluted EPS of $1.22 and an operating margin of 49.0%.
- Revenue
- $377M
- YoY growth
- +42.2%
- Diluted EPS
- $1.22
- Operating margin
- 49.0%
$377M
Revenue
+42.2%
YoY growth
$1.22
Diluted EPS
49.0%
Operating margin
01 Key takeaways
What management said
- •Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business, David Ramsay, our Interim Chief Financial Officer, will review our financial results as well as our outlook.
- •Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.
- •The continued strong performance of our currently approved products gives us strong conviction in the 2026-2028 financial guidance.
- •We have clear priorities for capital allocation, reinvesting at compelling returns to create new value and returning value to our shareholders.
- •The key drivers of revenue in the 2026 to 2028 timeframe are our first 10 ENHANZE launch products, which includes DARZALEX subcutaneous, VYVGART Hytrulo, and PHESGO.
- •Total revenue for the quarter increased 42% year-over-year to $377 million, reflecting the strength of our commercial royalty portfolio.
- •This revenue growth translated into adjusted EBITDA of $230 million and non-GAAP earnings per share of $1.60, representing a greater than 40% increase year-over-year.
- •Based on these results, I am pleased to reaffirm our full year 2026 financial guidance and the 2026 to 2028 financial guidance.
- •For 2026, we continue to project ENHANZE royalties to exceed $1 billion for the first time, representing 30%-35% growth over 2025.
- •During the 2026 to 2028 timeframe, we project our adjusted EBITDA margin will be greater than 65%, growing to approximately 70%.
- •As you know, our business converts revenue to free cash flow very efficiently, which provides us with the capital to deliver durable, long-term value for our shareholders.
- •During 2026 to 2028, we plan to deploy our capital predominantly in four key areas.
SourcesCompany financials · earnings call
Last updated